PCOS Just Got Renamed PMOS – What The Change Means

You may have seen the headlines this week: PCOS, the hormonal condition affecting more than 170 million people worldwide, has been officially renamed. A landmark paper published in The Lancet, and presented simultaneously at the European Congress of Endocrinology in Prague, announced that polycystic ovary syndrome will now be called polyendocrine metabolic ovarian syndrome, or PMOS. 

Only one letter changed in the acronym, so if your first reaction was some version of "they spent eleven years and 22,000 people on that?", I understand. But the name change is not the story. The story is everything the old name got wrong — and what it cost women for the better part of a century.

I've spent over a decade as an OB-GYN. I treat this condition in every form it takes: the patient whose only sign was slightly irregular cycles; the patient who seemed to have hit every marker at once; the teenager who sat across from me and said she just wanted to feel normal. What they all shared was a diagnosis named for a finding that, in many of them, wasn't even there.

The Name That Built The Wrong Box

In 1935, two American gynecologists described the clinical history of seven women with menstrual disorders, excess hair growth, and enlarged ovaries. Both of these doctors were men, naturally. They named the condition after themselves, Stein-Leventhal Syndrome, which was very much in keeping with a long tradition of men stamping their names on female anatomy they had just met. (See also: the Fallopian tubes, named by a 16th-century Italian anatomist whose primary research interest was actually the inner ear.) 

But I digress. The story was written around what they could see on an exam table in 1935, in seven patients, and it would take another 90 years to fully correct it.

In 1990, the National Institutes of Health (NIH) updated the name of Stein-Leventhal Syndrome to PCOS and codified three diagnostic criteria: 

1. Delayed ovulation
2. Excess androgen hormones
3. Polycystic ovaries

The word "polycystic" stuck, and with it a clinical framework that treated this as a disease of ovarian architecture, something you could confirm on an ultrasound and file under gynecology.

The problem is that the name provided an inaccurate description of a condition that does not actually manifest through cysts on the ovaries. Women who didn't present with visible cysts could be told they didn't have PCOS, even as they were living with insulin resistance, hormonal dysregulation, and all the downstream consequences of both. The term obscured the condition's diverse endocrine and metabolic features, contributed to delayed diagnosis and fragmented care, and curtailed research and policy attention. 

Helena Teede, an endocrinologist and professor of women's health at Monash University in Australia, who led the process to update the name to PMOS, has spent more than 25 years in clinical practice dispelling the misunderstanding that this condition is simply about cysts, a misunderstanding that has resulted in missed diagnoses and inaccurate treatment.

The World Health Organization (WHO) estimates that 70 percent of people with the condition are undiagnosed. That is not primarily a failure of individual clinicians — it's what happens when a disease is named for one visible feature while the rest of the picture is obscured.

What PMOS Actually Is

PMOS has never been a gynecological footnote confined to what shows up on an ultrasound. It's a whole-body hormonal disorder that medicine keeps trying to file in the wrong drawer.

The pathophysiology centers on insulin resistance and excess androgen production, which disrupts the hormonal communication between the hypothalamus, pituitary gland, and ovaries. The symptoms range from subtle to significant: irregular periods, acne, unwanted hair growth, weight changes that feel disproportionate to lifestyle, and difficulty conceiving. 

Over their lifetimes, women with PMOS have a meaningfully higher risk of developing infertility, high-risk pregnancy, miscarriage, diabetes, sleep apnea, obesity, endometrial cancer, depression, and heart disease. Insulin resistance is present in 35 to 80 percent of patients with PMOS, including those who are not obese, and is linked to elevated risks of impaired glucose tolerance, gestational diabetes, abnormal cholesterol, high blood pressure, and cardiovascular disease. 

This is a metabolic condition with reproductive consequences, not the reverse. The name had it backward.

The Stigma That Grew Inside The Wrong Name

There is a layer here that the clinical data doesn't fully capture. A condition defined by weight gain, unwanted hair, acne, and irregular periods was always going to carry shame alongside it in a culture with strong opinions about all of those things. And a name that implicated the ovaries, rather than the endocrine system, made it easier for women to conclude that their bodies had simply failed them in some fundamental way.

Women with PMOS experience anxiety, depression, eating disorders, and negative body image at elevated rates. Some of that is biology. Some of it is years of being handed a name that pointed at the wrong thing while the right thing went untreated. When asked about their top priority for renaming of this syndrome, women living PCOS said it wasn't scientific accuracy — it was avoiding stigma. Women knew before the researchers finished their analysis exactly what the name had been doing to them.

Eleven Years To Change One Letter

The push to rename began in October 2015 at a meeting in Sicily, where experts convened and found they couldn't coalesce around what to call it instead. Everyone in the room agreed the name was wrong, but no one could get to a solution.

What followed was the most robust and extensive disease-renaming process in history. It involved 56 leading academic, clinical, and patient organizations, with global surveys gathering input from more than 14,300 people with the condition and multidisciplinary health professionals from every world region. In total, roughly 22,000 people contributed over 11 years. Of 90 final voters — including clinicians, researchers, patients, and advocates — 87 supported the new name immediately.

Polyendocrine metabolic ovarian syndrome. Words that, for the first time, tell the truth about where this condition actually lives: in the endocrine system, in metabolism, and in the ovaries as one piece of a much larger picture.

What Changes With The Name

The rollout is planned over three years, with updates to guidelines used in 195 countries. When the name changes in the textbooks, this will guide clinician training. A woman who comes in with insulin resistance and irregular cycles, but nothing dramatic on ultrasound, doesn't get sent home. A teenager who doesn't fit the narrow visual profile of the old criteria doesn't spend years being told there's nothing to find.

The condition hasn't changed. The women haven't changed. What has changed is that medicine is finally using a name that describes what it's actually dealing with: a complex, systemic hormonal disorder that deserves to be taken seriously as one.

If you have PMOS, or think you might, or have ever been dismissed because your ultrasound looked unremarkable, you weren't wrong about your own body. The science was there. The name just kept getting in the way.

Read the article on Unbiased Science.